Small molecule · Inhibitor of fibroblast growth factor receptor 3 (FGFR3) and fibroblast growth factor receptor 4 (FGFR4) · developed by Tyra Biosciences
TYRA-430 is an orally bioavailable, reversible inhibitor of fibroblast growth factor receptors 3 and 4 (FGFR3/4). It binds these receptors and blocks signaling mediated by the ligand FGF19, which is studied in tumors that overexpress FGF19 or FGFR4, including hepatocellular carcinoma and other solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06915753 | Phase 1 | Metastatic Hepatocellular Carcinoma | Recruiting | TYRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsFGF19 Gene AmplificationFGF19 Gene OverexpressionFGFR Gene AlterationsFGFR Gene AmplificationFGFR4 Gene FusionsFGFR4 Gene MutationLocally Advanced Unresectable Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaSolid Tumor, AdultSolid Tumors
Updated Nov 1, 2026. Something wrong or missing? Report it on the TYRA page.
See TYRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TYRA catalysts and pipeline →